NCT06423872View on ClinicalTrials.gov

A SAD Study of ZT002 Injection in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

October 20, 2023

Study Completion Date

December 8, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ZT002

Participants will receive a single subcutaneous (SC) ZT002 injection.

OTHER

Placebo

Participants will receive same volume as of the study drug.

Trial Locations (1)

Unknown

Beijing Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Beijing Hospital

OTHER_GOV

lead

Beijing QL Biopharmaceutical Co.,Ltd

INDUSTRY